The deal will expand Wright’s direct sales channel in France and international distribution network and add Biotech’s complementary extremity product portfolio.
With the closing of the deal, a total of approximately $55m in cash will be paid, and approximately 742,115 shares of Wright common stock will be issued.
All Wright common stock issued in connection with the transaction is subject to a one-year lockup.
As a result of closing this transaction, the company anticipates full-year 2013 sales to be at the high end of its net sales range of $237m to $240m and no change to its adjusted loss range of $0.59 to $0.55 per share.
